Gendelman Samantha R, Pien Lily C, Gutta Ravi C, Abouhassan Susan R
Department of Allergy and Immunology, Cleveland Clinic Foundation, Respiratory Institute, Cleveland, Ohio, USA.
Allergy Rhinol (Providence). 2014 Mar;5(2):66-9. doi: 10.2500/ar.2014.5.0080. Epub 2014 Mar 7.
The Center for Disease Control guidelines recommend desensitization to metronidazole in patients with trichomoniasis and hypersensitivity to metronidazole. There is only one published oral metronidazole desensitization protocol. The purpose of this study was to design a new, more gradual oral desensitization protocol to decrease systemic reactions that may occur when using the previously published protocol. We present two patients with presumed IgE-mediated allergy to metronidazole who underwent oral desensitization using our modified protocol. Case 1 was a 65-year-old woman with trichomoniasis who presented for metronidazole desensitization with a history of intraoperative anaphylaxis and positive skin tests to metronidazole. The patient tolerated six doses of the modified desensitization but developed systemic symptoms of nasal congestion and diffuse pruritus after the 25- and 100-mg doses. Both reactions were treated with intravenous (i.v.) antihistamines. Because of gastrointestinal irritation, the desensitization was completed at a dose of 250 mg orally every 6 hours. Case 2 was a 42-year-old woman with trichomoniasis and a history of hives immediately after administration of i.v. metronidazole who presented for desensitization. The patient had negative skin-prick and intradermal testing to metronidazole. She developed lip tingling and pruritus on her arms 15 minutes after the 10-mg dose. Fexofenadine at 180 mg was given orally and symptoms resolved. She tolerated the rest of the protocol without reaction and received a total dose of 2 g of metronidazole. Our oral metronidazole desensitization for presumed IgE-mediated reactions offers a second option for physicians wishing to use a more gradual escalation in dose.
疾病控制中心指南建议,对于患有滴虫病且对甲硝唑过敏的患者,应进行甲硝唑脱敏治疗。目前仅有一种已发表的口服甲硝唑脱敏方案。本研究的目的是设计一种新的、更为渐进的口服脱敏方案,以减少使用先前发表的方案时可能发生的全身反应。我们报告了两名推测对甲硝唑有IgE介导过敏反应的患者,他们使用我们改良的方案进行了口服脱敏治疗。病例1是一名65岁患有滴虫病的女性,因甲硝唑脱敏前来就诊,有术中过敏史且对甲硝唑皮肤试验呈阳性。患者耐受了六剂改良脱敏治疗,但在服用25毫克和100毫克剂量后出现了鼻塞和全身瘙痒的全身症状。两种反应均用静脉注射抗组胺药治疗。由于胃肠道刺激,脱敏治疗以每6小时口服250毫克的剂量完成。病例2是一名42岁患有滴虫病的女性,静脉注射甲硝唑后立即出现荨麻疹病史,前来进行脱敏治疗。该患者对甲硝唑的皮肤点刺试验和皮内试验均为阴性。她在服用10毫克剂量后15分钟出现嘴唇刺痛和手臂瘙痒。口服180毫克非索非那定后症状缓解。她耐受了方案的其余部分,没有出现反应,共接受了2克甲硝唑。我们针对推测的IgE介导反应的口服甲硝唑脱敏为希望更渐进增加剂量的医生提供了第二种选择。